<DOC>
	<DOCNO>NCT02244801</DOCNO>
	<brief_summary>This Phase I pilot study evaluate safety , tolerability darTreg infusion adult , de novo , live donor renal transplant recipient .</brief_summary>
	<brief_title>Donor-Alloantigen-Reactive Regulatory T Cell ( darTreg ) Therapy Renal Transplantation ( The ONE Study )</brief_title>
	<detailed_description>A single-center , open-label , dose-escalation pilot trial single infusion darTregs two dosing cohort . This study independent single-center clinical trial . However , organizational mechanistic infrastructure study provide ONE Study project , European Union fund collaborative project , whose objective ass distinct purify hematopoietic immunoregulatory cell clinical therapy solid organ transplantation . This study one multiple clinical trial within framework The ONE Study project , base general design .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<criteria>( organ donor eligibility ) 1 . Eligible live kidney donation 2 . At least 18 year age 3 . An ABO blood type compatible organ recipient 4 . Willing able provide blood sample The ONE Study IM ( Immune Monitoring ) Subproject 5 . Willing provide personal medical/biological data trial analysis 6 . Eligible give blood B cell source prior organ donation 7 . Signed date write informed consent* . *For subject unable read and/or write , oral inform consent observe independent witness acceptable subject fully understood oral information give Investigator . The witness sign consent form behalf subject . In sign donor information sheet/informed consent form ( DIS/ICF ) , organ donor agree undergo phlebotomy provide donor B cell production darTreg , provide blood sample IM Subproject , permit access medical record collection specify demographic medical/biological data trial . Organ Recipient eligibility : A prospective kidney transplant recipient eligible enrollment study follow inclusion criterion apply : 1 . Chronic renal insufficiency necessitate kidney transplantation approve receive primary kidney allograft live donor 2 . At least 18 year age 3 . Able commence immunosuppressive regimen protocolspecified time point 4 . Willing able participate The ONE Study IM HEC ( HealthEconomics Subproject ) subprojects 5 . Adequate venous access support leukapheresis 6 . Signed date write informed consent* . For patient unable read and/or write , oral inform consent observe independent witness acceptable patient fully understood oral information give Investigator . The witness sign consent form behalf patient . ( organ donor ) If prospective donor fulfills follow criterion , ineligible trial : 1 . Genetically identical prospective organ recipient HLA ( human leukocyte antigen ) locus ( 000 mismatch ) 2 . CMVpositive donate CMVnegative recipient 3 . Exposure investigational agent time kidney donation , within 28 day prior kidney donation 4 . Any form substance abuse , psychiatric disorder , condition , opinion Investigator , may invalidate communication Investigator and/or designate study personnel 5 . Subjects unable freely give inform consent ( e.g . individual legal guardianship ) . Exclusion criterion ( organ recipient ) 1 . Patient previously receive tissue organ transplant plan kidney graft 2 . Known contraindication protocolspecified treatment / medication 3 . Genetically identical prospective organ donor HLA ( human leukocyte antigen ) locus ( 000 mismatch ) 4 . PRA ( panel reactive antibody ) grade &gt; 40 % within 6 month prior enrollment 5 . Previous treatment desensitization procedure ( without IVIg ) 6 . Concomitant malignancy history malignancy within 5 year prior plan study entry ( exclude successfullytreated nonmetastatic basal/squamous cell carcinoma skin ) 7 . Evidence significant local systemic infection 8 . HIVpositive , EBVnegative suffer chronic viral hepatitis 9 . CMVnegative receive kidney CMVpositive donor 10 . Significant liver disease , define persistently elevate AST ( aspartate aminotransferase ) and/or ALT ( alanine aminotransferase ) level &gt; 2 x ULN ( Upper Limit Normal range ) 11 . Malignant premalignant hematological condition 12 . Neutrophils &lt; 1000/μl ; platelet &lt; 100,000/μl 13 . Regulatory T cell present peripheral blood &lt; 30/µL 14 . Any uncontrolled medical condition concurrent disease could interfere study objective 15 . Any condition , judgment Investigator , would place subject undue risk 16 . Ongoing treatment systemic immunosuppressive drug study entry 17 . Patients receive antiT cell therapy within 30 day prior transplant surgery 18 . Participation another clinical trial study within 28 day prior plan study entry 19 . Female patient reproductive potential positive pregnancy test enrollment 20 . Female patient breastfeed 21 . All female patient reproductive potential* UNLESS patient willing use acceptable birth control duration study unless patient chooses abstinence ( choose avoid heterosexual intercourse completely ) ( See Table 2 . Acceptable Contraception Methods Females Reproductive Potential ) 22 . Male patient unwilling use reliable effective form contraception 3 month darTreg dose 23 . Psychological , familial , sociological geographical factor potentially hamper compliance study protocol followup visit schedule 24 . Any form substance abuse , psychiatric disorder , condition , opinion Investigator , may invalidate communication Investigator and/or designate study personnel 25 . Patients unable freely give inform consent ( e.g . individual legal guardianship ) . Females reproductive potential include girl enter puberty woman uterus pass menopause . Menopause permanent end menstruation fertility . Menopause clinically confirm patient 's healthcare practitioner . Some commonly use diagnostic criterion include 1 ) 12 month spontaneous amenorrhea ( amenorrhea induce medical condition medical therapy ) 2 ) postsurgical bilateral oophorectomy . Exclusion Criteria B ( organ recipient ) Below exclusion criterion assess posttransplantation prior darTreg infusion . Subjects meet criterion receive darTreginfusion : 1 . Unacceptable darTreg product . 2 . Delayed graft function ( require dialysis posttransplant ) . 3 . Requiring oxygen supplementation keep capillary oxygen saturation &gt; 95 % . 4 . Any medical technical complication ( e.g . myocardial infarction , urine leak , wound dehiscence , pneumonia , ongoing fever , etc . ) judgment investigator responsible clinician would put subject undue risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>